Adaptive Biotechnologies is turning clonoSEQ into a scalable, high‑margin MRD diagnostics engine—racing toward profitability while competition and reimbursement remain the swing factors.
Overview
Adaptive Biotechnologies is a commercial-stage precision medicine company built around decoding the adaptive immune system at scale using high-throughput immunosequencing and bioinformatics to identify and track immune cell clones with very high sensitivity. The business is anchored by two segments: Minimal Residual Disease (MRD) and Immune Medicine (IM). MRD is the core revenue and profit engine, driven by clonoSEQ—an FDA-cleared in vitro diagnostic for MRD detection/tracking in multiple myeloma, B-ALL, and CLL (and offered as an LDT in additional lymphomas). In 2025, the company produced ~$277M of total revenue (+55% YoY), with MRD contributing ~$212.3M (~77% of revenue and 86% of Q4), reflecting accelerating clinical adoption across academic and community settings (community physicians represented ~33% of Q4 volume). Growth is supported by expanding blood-based monitoring, broader guideline inclusion (NCCN), and reimbursement wins (e.g., Medicare recurrence monitoring expansion in MCL). IM has been strategically reorganized away from capital-intensive drug development toward monetizing its large TCR-antigen database through data licensing; two non-exclusive licensing deals with Pfizer in late 2025 provide a blueprint for scalable, high-margin digital biology revenues.